Prestige Consumer Healthcare Inc.
PBHHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 5, 2026
Scan Results
Daily timeframePrestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America,. The company carries a $2.48B market cap, placing it firmly in the mid-cap category. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Market Cap
$2.48B
Beta
0.33
P/E (TTM)
14.64
P/E (Fwd)
10.28
EPS (TTM)
$3.57
EPS (Fwd)
$5.08
ROE
9.1%
ROA
4.6%
Cash
$89.1M
Total Debt
$2.07B
Free CF
$147.9M
52W Change
-19.2%
Annual Financials
Cash vs Debt
Where PBH stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PBH finished 4.19% below its 150-day moving average ($55.14) and 7.10% below its 200-day moving average ($56.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PBH overbought or oversold?
At the September 3, 2026 close, PBH's RSI(14) was 56.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Prestige Consumer Healthcare Inc. carries $2.07B in total debt against $89.1M in cash reserves — debt is roughly 23.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $147.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 9.1% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.6% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $1.13B (2023) to $1.09B (2026).
With a beta below 0.7, Prestige Consumer Healthcare Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Prestige Consumer Healthcare Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing PBH's risk profile alongside its fundamentals and technical indicators provides a more complete picture.